Results 41 to 50 of about 231,116 (154)
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. [PDF]
, 2022 BACKGROUND: In recent years, a series of clinical trials have explored the application of neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer (NSCLC).
Jiang, Juan +9 more
core +1 more source
DataSheet_1_Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.pdf
, 2022 BackgroundNeoadjuvant immunotherapy has preliminarily been effective in multiple resectable cancers. However, its safety is still largely unknown.MethodsA systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library ...
Yongfeng Wu (4241674) +6 more
core +1 more source
Frontiers in Oncology, 2021 Neoadjuvant immunotherapy has the potential to enhance clinical outcomes by increasing anti-tumor immune responses in the presence of abundant tumor-derived antigen in an immune microenvironment that has not been exposed to previous therapy.
Hirofumi Shibata +5 more
doaj +1 more source
Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
, 2023 Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease due to its late presentation and tendency to recur early even after optimal surgical resection. Currently, there are limited options for effective systemic therapy.
Jordan M. Cloyd +3 more
core +1 more source
Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. [PDF]
, 2021 Background There is a paucity of biomarkers that can predict the degree of pathological response [e.g., pathological complete response (pCR) or major response (pMR)] to immunotherapy.
Peng, Ren-Wang +11 more
core +2 more sources
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus
, 2013 AIM: To assess tumour regression grade (TRG) and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS: Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal ...
Kelly, Jamie +10 more
core +1 more source
Frontiers in ImmunologyBackgroundImmune checkpoint inhibitors have demonstrated promising therapeutic outcomes in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC), prompting numerous clinical trials to investigate the safety and efficacy of this ...
Chang Liu +7 more
doaj +1 more source
npj Precision Oncology, 2022 Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83% patients can benefit from it.
Shuhang Wang +14 more
doaj +1 more source
Frontiers in Immunology, 2023 ObjectiveThis systematic review and meta-analysis aimed to explore the efficacy and safety of neoadjuvant immunotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC).BackgroundSeveral studies have reported the ...
Wenwu He +11 more
doaj +1 more source
BMJ Open, 2023 Introduction Neoadjuvant chemotherapy (NACT) is an emerging approach for locally advanced cervical cancer (LACC). However, the clinical response and postoperative adjuvant radiation or chemoradiation trimodality treatment resulted in controversy.
Jing Chen +8 more
doaj +1 more source